Trastuzumab in combination with AT-101 induces cytotoxicity and apoptosis in Her2 positive breast cancer cells

Simple item page
dc.contributor.authorBulut G.
dc.contributor.authorAtmaca H.
dc.contributor.authorKaraca B.
dc.date.accessioned2024-07-22T08:09:03Z
dc.date.available2024-07-22T08:09:03Z
dc.date.issued2019
dc.description.abstractAim: AT-101 is a polyphenolic compound with potent anti-apoptotic effects in various cancers. In this study, the possible synergistic cytotoxic and apoptotic effect of trastuzumab/AT-101 combination was investigated in HER2-positive breast cancer cell lines. Materials & methods: SKBR-3, MDA-MB-453 and MCF-10A cell lines were treated with a trastuzumab/AT-101 combination. Synergistic cytotoxicity and apoptosis effects were shown and then PI3K and Akt protein levels were studied. Result: The trastuzumab/AT-101 combination induced synergistic cytotoxicity and apoptosis in both breast cancer cells but not in MCF-10A cells. Combination treatment induced cytotoxicity via inhibiting PI3K/AKT but not the MAPK/ERK pathway. Conclusion: The trastuzumab/AT-101 combination may be a good candidate for patients with trastuzumab-resistant Her2-positive breast cancer and inhibition of the PI3K/AKT pathway may be one of the underlying mechanisms. © 2019 Gulcan Bulut, Harika Atmaca & Burcak Karaca.
dc.identifier.DOI-ID10.2217/fon-2019-0521
dc.identifier.issn14796694
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/14648
dc.language.isoEnglish
dc.publisherFuture Medicine Ltd.
dc.rightsAll Open Access; Hybrid Gold Open Access
dc.subjectAntineoplastic Agents, Immunological
dc.subjectAntineoplastic Agents, Phytogenic
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectApoptosis
dc.subjectBreast Neoplasms
dc.subjectCell Line, Tumor
dc.subjectDrug Screening Assays, Antitumor
dc.subjectDrug Synergism
dc.subjectFemale
dc.subjectGossypol
dc.subjectHumans
dc.subjectPhosphatidylinositol 3-Kinases
dc.subjectProto-Oncogene Proteins c-akt
dc.subjectReceptor, ErbB-2
dc.subjectSignal Transduction
dc.subjectTrastuzumab
dc.subjectisosorbide
dc.subjectmitogen activated protein kinase
dc.subjectphosphatidylinositol 3 kinase
dc.subjectprotein kinase B
dc.subjecttrastuzumab
dc.subjectantineoplastic agent
dc.subjectepidermal growth factor receptor 2
dc.subjectERBB2 protein, human
dc.subjectgossypol
dc.subjectgossypol acetic acid
dc.subjectimmunological antineoplastic agent
dc.subjectphosphatidylinositol 3 kinase
dc.subjectprotein kinase B
dc.subjecttrastuzumab
dc.subjectapoptosis
dc.subjectArticle
dc.subjectbreast cancer
dc.subjectcancer cell
dc.subjectcontrolled study
dc.subjectcytotoxicity
dc.subjectdrug effect
dc.subjectdrug inhibition
dc.subjectdrug mechanism
dc.subjectdrug potentiation
dc.subjecthuman
dc.subjecthuman cell
dc.subjectMCF-10A cell line
dc.subjectMDA-MB-453 cell line
dc.subjectpriority journal
dc.subjectsignal transduction
dc.subjectSK-BR-3 cell line
dc.subjectapoptosis
dc.subjectbreast tumor
dc.subjectdrug screening
dc.subjectfemale
dc.subjectmetabolism
dc.subjectpathology
dc.subjecttumor cell line
dc.titleTrastuzumab in combination with AT-101 induces cytotoxicity and apoptosis in Her2 positive breast cancer cells
dc.typeArticle

Files

Collections

Scopus Koleksiyonu